כל המחקרים
גיוסשלב 3התערבותי

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

This research study is testing a new medicine called AZ-3102 for rare genetic conditions that affect children and young people. These conditions are Niemann-Pick Type C disease, GM1 gangliosidosis, and GM2 gangliosidosis. The study wants to find out if AZ-3102 is safe to use and if it can help improve the health of those with these conditions. For 18 months, some participants will receive the new medicine, while others will receive a dummy pill (placebo). This helps us understand if any changes are due to the medicine itself. Doctors and participants won't know who is getting which treatment. Researchers will carefully monitor everyone involved to understand the medicine's effects.

במבט חטוף

סטטוס
גיוס
שלב
שלב 3
נותן חסות
Azafaros B.V.
יעד הרשמה
147
התחל
30 יוני 2025
השלמה משוערת
14 ביוני 2028

על מה המחקר הזה?

This study is a research project looking into a new medicine called AZ-3102. It's designed for people, mainly children and young adults, who have one of three rare genetic conditions: Niemann-Pick Type C disease, GM1 gangliosidosis, or GM2 gangliosidosis. These conditions can cause problems with how the body processes certain fats and sugars, leading to various health issues. The main goal is to see if AZ-3102 can safely help improve the health of individuals living with these conditions.

This kind of study involves different groups of people. Some will receive the new medicine, AZ-3102, while others will receive a 'placebo', which looks exactly like the medicine but contains no active ingredients. This is a common way to test new treatments, as it helps researchers figure out if any improvements are genuinely due to the medicine being tested, rather than other factors. Neither the participants, their families, nor their doctors will know who is getting the medicine and who is getting the placebo until the study is over.

The study will last for 18 months, and participants will be closely monitored by a team of medical professionals. They will gather information about the health of everyone involved to see if AZ-3102 makes a difference. Because these conditions have specific features, the study is set up so that information is collected carefully for each condition, even though they are all part of the same overall research programme.

נקודות עיקריות

  • This study is testing a new medicine (AZ-3102) for rare genetic conditions.
  • It's for children and young people aged 4 and over with specific diagnoses.
  • The study lasts 18 months and involves regular clinic visits.
  • Participants will receive either the new medicine or a dummy pill (placebo).
  • Neither you nor your doctor will know which treatment you are getting during the study.
  • Your safety and well-being will be closely monitored throughout.

מי עשוי להיות זכאי?

This study is looking for children and young people who have been diagnosed with certain forms of Niemann-Pick Type C disease, GM1 Gangliosidosis, or GM2 Gangliosidosis.

To be considered, you must be at least 4 years old and have a diagnosis of one of these conditions, specifically the 'late-infantile' or 'juvenile' type. There are also other specific health requirements for each condition that your doctor would need to check.

Generally, those who don't meet these age or diagnosis criteria, or have other certain health issues that might affect the study results, would not be able to take part. Your doctor will have more detailed information about who can and cannot join based on your specific health situation.

האם מחקר זה יכול להתאים לך?

ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.

  1. Are you or your child diagnosed with Niemann-Pick Type C, GM1 Gangliosidosis, or GM2 Gangliosidosis?
  2. Is the diagnosis specifically the 'late-infantile' or 'juvenile' form?
  3. Is the person wanting to take part aged 4 years or older?
  4. Are you able to attend regular clinic visits for 18 months?
  5. Are you willing to potentially receive either the study medicine or a placebo?
ענה על כל שאלה כדי לראות את התוצאה שלך.

מה כרוך בהשתתפות?

If you decide to take part in this study, you would be involved for a total of 18 months. During this time, you would regularly take the study medication, either AZ-3102 or the placebo, by mouth as instructed by the study doctor. You would have a schedule of visits to the study clinic where the medical team will carry out various checks and assessments.

These assessments might include physical examinations, blood tests, and tests to measure how your condition is affecting you. The exact number and type of visits and tests will depend on which specific condition you have, but they are all designed to keep you safe and to see if the medicine is working. The study team will explain the full schedule of visits and what each involves before you make a decision.

סיכונים ותועלות פוטנציאליים

Taking part in any medical study has both potential benefits and risks. A potential benefit of this study is that AZ-3102 might help improve your health condition, or it could help researchers learn more about these rare diseases and potential future treatments, which could benefit others. However, there's also a chance the medicine might not help, or you might experience side effects. It's important to remember that you can choose to leave the study at any time, for any reason, without it affecting your medical care.

מיקומים (39)

  • UCSF Children's Hospital and Research Center at Oakland
    מיקוד מאומת
    אוקלנד, ארצות הברית· גיוס
  • University of Minnesota Medical School
    מיקוד מאומת
    מיניאפוליס, ארצות הברית· גיוס
  • Mayo Clinic Childrens Center - PIN
    מיקוד מאומת
    רוצ'סטר, ארצות הברית· גיוס
  • Children's Medical Center Dallas
    מיקוד מאומת
    דאלאס, ארצות הברית· גיוס
  • Lysosomal Rare Disorders Research and Treatment Center
    מיקוד מאומת
    פיירפקס, ארצות הברית· גיוס
  • Hospital Universitario Austral
    עיר בלבד
    Ciudad Autónoma Buenos Aires, Argentina· פעיל אך לא מגייס
  • Hospital de Niños de La Santisima Trinidad
    מיקוד מאומת
    קורדובה, ארגנטינה· גיוס
  • Women's and Children's Hospital
    מיקוד מאומת
    North Adelaide, Australia· גיוס
  • Royal Melbourne Hospital
    מיקוד מאומת
    Parkville, Australia· גיוס
  • Royal Children's Hospital Melbourne - PIN
    מיקוד מאומת
    Parkville, Australia· גיוס
  • Instituto Fernandes Figueira
    מיקוד מאומת
    Rio de Janeiro, Brazil· גיוס
  • Hospital de Clinicas de Porto Alegre (HCPA) - PPDS
    מיקוד מאומת
    פורטו אלגרה, ברזיל· גיוס

שאלות נפוצות

What is AZ-3102?

AZ-3102 is a new medicine being tested in this study to see if it can help people with Niemann-Pick Type C, GM1 Gangliosidosis, or GM2 Gangliosidosis.

כמה זמן יימשך המחקר?

If you join, your active participation in the study will last for 18 months.

Will I know if I'm getting the medicine or a dummy pill?

No, neither you, your family, nor your doctors will know whether you are receiving AZ-3102 or the placebo until the study is over.

Can I stop taking part in the study?

Yes, you can choose to leave the study at any time, for any reason, without it affecting your usual medical care.

Why is a placebo used in this study?

A placebo helps researchers determine if any changes or improvements are truly due to the new medicine, AZ-3102, rather than other factors.

כיצד לגלות עוד

Patient Advocacy Representative

תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.

מעוניינים להשתתף?

רשום את התעניינותך

שתף את הפרטים שלך וצוות המחקר עבור "A Study to Evaluate the Safety and Efficacy of Oral Nizubagl…" ייצרו איתך קשר אם אתה עשוי להיות זכאי. תמיד התייעץ עם הרופא שלך לפני שאתה מסכים להשתתף.

דיון

דיון קהילתי

מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.